AIM: To evaluate the utility of the innovative fecal tumor M2-Pyruvate kinase (M2-PK) test in our daily clinical routine, as a marker for the pre-selection of patients who should subsequently undergo colonoscopy for the diagnosis or exclusion of colorectal cancer. METHODS: Fecal tumor M2-PK was measured in stool samples of 96 study participants (33 patients with colorectal cancer, 21 patients with rectal carcinoma and 42 controls) who all underwent total colonoscopy. RESULTS: In 39 of 42 individuals in the control group, fecal tumor M2-PK was below 4.0 kU/L (93% specificity). Colorectal tumors were accompanied by a highly significant increase (P < 0.001) in fecal tumor M2-PK levels (median: colon carcinoma, 23.1 kU/L; rectal carcinoma, 6.9 kU/L; colorectal carcinoma, 14.7 kU/L), which correlated with Duke's staging and T-classification. The overall sensitivity was 78% for colorectal cancer, increasing from 60% for stage T1 to 100% for stage T4 and from 60% for Duke's A to 90% for Duke's D tumors. CONCLUSION: Fecal tumor M2-PK is an appropriately sensitive tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
AIM: To evaluate the utility of the innovative fecal tumor M2-Pyruvate kinase (M2-PK) test in our daily clinical routine, as a marker for the pre-selection of patients who should subsequently undergo colonoscopy for the diagnosis or exclusion of colorectal cancer. METHODS: Fecal tumor M2-PK was measured in stool samples of 96 study participants (33 patients with colorectal cancer, 21 patients with rectal carcinoma and 42 controls) who all underwent total colonoscopy. RESULTS: In 39 of 42 individuals in the control group, fecal tumor M2-PK was below 4.0 kU/L (93% specificity). Colorectal tumors were accompanied by a highly significant increase (P < 0.001) in fecal tumor M2-PK levels (median: colon carcinoma, 23.1 kU/L; rectal carcinoma, 6.9 kU/L; colorectal carcinoma, 14.7 kU/L), which correlated with Duke's staging and T-classification. The overall sensitivity was 78% for colorectal cancer, increasing from 60% for stage T1 to 100% for stage T4 and from 60% for Duke's A to 90% for Duke's D tumors. CONCLUSION: Fecal tumor M2-PK is an appropriately sensitive tool to pre-select those patients requiring colonoscopy for the further diagnostic confirmation or exclusion of colorectal cancer.
Authors: D Lüftner; J Mesterharm; C Akrivakis; R Geppert; P E Petrides; K D Wernecke; K Possinger Journal: Anticancer Res Date: 2000 Nov-Dec Impact factor: 2.480
Authors: Giovanni Traverso; Anthony Shuber; Louise Olsson; Bernard Levin; Constance Johnson; Stanley R Hamilton; Kevin Boynton; Kenneth W Kinzler; Bert Vogelstein Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: S M Dong; G Traverso; C Johnson; L Geng; R Favis; K Boynton; K Hibi; S N Goodman; M D'Allessio; P Paty; S R Hamilton; D Sidransky; F Barany; B Levin; A Shuber; K W Kinzler; B Vogelstein; J Jen Journal: J Natl Cancer Inst Date: 2001-06-06 Impact factor: 13.506
Authors: Kuldeep S Tagore; Michael J Lawson; Joy A Yucaitis; Rhonda Gage; Tashia Orr; Anthony P Shuber; Michael E Ross Journal: Clin Colorectal Cancer Date: 2003-05 Impact factor: 4.481
Authors: Sarah Strohkamp; Timo Gemoll; Sina Humborg; Sonja Hartwig; Stefan Lehr; Sandra Freitag-Wolf; Susanne Becker; Bo Franzén; Ralph Pries; Barbara Wollenberg; Uwe J Roblick; Hans-Peter Bruch; Tobias Keck; Gert Auer; Jens K Habermann Journal: Cell Mol Life Sci Date: 2017-08-28 Impact factor: 9.261
Authors: Mallikarjuna Uppara; Franklin Adaba; Alan Askari; Susan Clark; George Hanna; Thanos Athanasiou; Omar Faiz Journal: World J Surg Oncol Date: 2015-02-13 Impact factor: 2.754